Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0003864 (arthritis)
 69,039 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

ALCAT Test results were the base for elimination diet treatment in several ailments regarded as the result of food allergy (intolerance) in 72 patients (45 children and 27 adults). The best results were achived in arthritis, urticaria, bronchitis, gastroenteritis (83%, 75%, 70% of improvement in treated patients respectively). Worse results were observed in children hypereactivity, rhinitis and atopic dermatitis (32%, 47%, 49% of improvement respectively). Less satisfactory effects of the elimination diet treatment based on the ALCAT Test results in the two latter diseases may result from the considerable involvement of IgE-mediated mechanism in the pathology of the skin and nose, which are under a great influence of external environmental factors other than food. In 57% of patients skin prick tests were positive (in 35% with inhalants and foods, 12% with inhalants only, in 9% with foods only).
 ...
PMID:ALCAT Test results in the treatment of respiratory and gastrointestinal symptoms, arthritis, skin and central nervous system. 877 17

About 200 individuals aged 60 years and above, out of 317 total geriatric population of a small village in Tamil Nadu were subjected for complete clinical examinations with the objective of finding major health problems and associated social problems prevalent among these study population. Main causes of illness were found to be arthritis, cataract, bronchitis, skin diseases and malnutrition.
 ...
PMID:A study of health and health related social problems in the geriatric population in a rural area of Tamil Nadu. 1038 98

Gliclazide modified release (MR) is a new formulation of the drug gliclazide and is given once daily. The hydrophilic matrix of hypromellose-based polymer in the new formulation effects a progressive release of the drug which parallels the 24-hour glycaemic profile in untreated patients with type 2 diabetes mellitus. The formulation shows high bioavailability and its absorption profile is unaffected by coadministration with food. Mean plasma glucose levels are significantly reduced over a 24-hour period in patients with type 2 diabetes mellitus treated with gliclazide MR once daily, in both fasting and postprandial states. No cardiovascular ATP-sensitive potassium channel interaction has been observed at therapeutic concentrations of gliclazide MR. Gliclazide MR has also demonstrated antioxidant properties that are independent of glycaemic control. In a randomised, double-blind, multicentre study, gliclazide MR 30 to 120 mg once daily showed similar efficacy to gliclazide immediate release (IR) 80 to 320 mg/day (in divided doses for doses >80 mg) in patients with type 2 diabetes mellitus over a 10-month period, reducing glycosylated haemoglobin (HbA(1c)) and fasting plasma glucose (FPG) to a similar extent. The drug appeared most efficacious in patients who had previously been treated by diet alone, where significant reductions in HbA(1c) from baseline of 0.9% and 0.95% were seen at 10 and 24 months. Similarly, a sustained effect of gliclazide MR was observed in a subgroup of elderly patients defined a priori; HbA(1c) was decreased to a similar degree to that observed in the general study population. Gliclazide MR showed similar tolerability to gliclazide IR after 10 months' treatment in the randomised trial. The most commonly observed adverse events were arthralgia, arthritis, back pain and bronchitis (each <5%). Bodyweight remained stable. In this study no episodes of nocturnal hypoglycaemia or hypoglycaemia requiring third party assistance were observed during treatment with gliclazide MR. Episodes of symptomatic hypoglycaemia were infrequent, occurring in approximately 5% of patients.
 ...
PMID:Gliclazide modified release. 1207 88

Rapid serum agglutination, haemagglutination inhibition and enzyme-linked immunosorbent assays were used to screen Swiss fancy breed chicken flocks for antibodies against 12 avian infectious agents. For this purpose, 1,002 blood samples from 40 flocks were collected and tested. Ten percent of the samples were positive for Salmonella gallinarum-pullorum and 62.5% of the flocks were affected. More than 75% of the flocks had antibodies against Mycoplasma gallisepticum/Mycoplasma synoviae, infectious bronchitis, infectious bursal disease, avian encephalomyelitis, infectious chicken anaemia and reoviral arthritis. Low prevalence of antibodies was recorded for Salmonella enteritidis, avian influenza, avian leukosis and Newcastle disease (2.0 to 4.0%).
 ...
PMID:Serological monitoring of 40 Swiss fancy breed poultry flocks. 1239 60

A 13 year old girl presented with auricular chondritis and recurrent episodes of unexplained chest pain, arthritis, bronchitis, conjunctivitis, prolonged steroid resistant alopecia areata, and a history of recurrent tonsillitis. Both the mosaic of autoimmunity and relapsing polychondritis were considered in the differential diagnosis. The patient was successfully treated with co-trimoxazole. The significance of co-trimoxazole, which is an antibiotic and an immunomodulatory drug, in the treatment of autoimmune disease is discussed.
 ...
PMID:Alopecia areata and relapsing polychondritis or mosaic autoimmunity? The first experience of co-trimoxazole treatment. 1286 Jul 37

Human T-lymphotropic virus types I and II (HTLV-I and -II) cause myelopathy; HTLV-I, but not HTLV-II, causes adult T-cell leukemia. Whether HTLV-II is associated with other diseases is unknown. Using survival analysis, we studied medical history data from a prospective cohort of HTLV-I- and HTLV-II-infected and -uninfected blood donors, all HIV seronegative. A total of 152 HTLV-I, 387 HTLV-II, and 799 uninfected donors were enrolled and followed for a median of 4.4, 4.3, and 4.4 years, respectively. HTLV-II participants had significantly increased incidences of acute bronchitis (incidence ratio [IR] = 1.68), bladder or kidney infection (IR = 1.55), arthritis (IR = 2.66), and asthma (IR = 3.28), and a borderline increase in pneumonia (IR = 1.82, 95% confidence interval [CI] 0.98 to 3.38). HTLV-I participants had significantly increased incidences of bladder or kidney infection (IR = 1.82), and arthritis (IR = 2.84). We conclude that HTLV-II infection may inhibit immunologic responses to respiratory infections and that both HTLV-I and -II may induce inflammatory or autoimmune reactions.
 ...
PMID:Respiratory and urinary tract infections, arthritis, and asthma associated with HTLV-I and HTLV-II infection. 1507 5

Human T-lymphotropic virus type II (HTLV-II) is a human retrovirus which is endemic in Amerindian and pygmy tribes. Molecular subtypes show geographic segregation consistent with an ancient origin of this virus within humans in Africa or South America. More recently, injection drug users in the United States and Europe have become infected with HTLV-II, and secondary sexual transmission has introduced the virus at low levels into the general population and blood donors. HTLV-II has been linked with a spastic paraparesis called HTLV-associated myelopathy / tropical spastic paraparesis (HAM/TSP), and perhaps with other neurological syndromes. It is also associated with an increased incidence of pneumonia and bronchitis, inflammatory conditions such as arthritis, and perhaps with increased mortality. Except for a few cases of cutaneous lymphoma in patients coinfected with HIV, there is no evidence that HTLV-II causes lymphoproliferative disease. HTLV-II and HIV coinfection has not been proven to alter the course of HIV disease, but such patients may have altered levels of CD4+ and CD8+ lymphocytes, and antiretroviral therapy may paradoxically increase HTLV-II proviral load.
 ...
PMID:The epidemiology and disease outcomes of human T-lymphotropic virus type II. 1559 31

From July 1999 to June 2004, we evaluated Streptococcus pneumoniae bacteremia in 40 children in Kamikawa and Soya Subprefectures in Hokkaido by obtaining the patient's information from 7 out of 9 hospitals in the area. The incidences of S. pneumoniae bacteremia in children aged < 2 years and < 5 years were 79.1 and 63.4. Median age was 19.6 months with a range from 4 months to 4 years. Thirty-one (77.5%) of the total were less than 2 years old. All of the children were admitted. The diagnoses were occult bacteremia in 12 patients, pneumonia or bronchitis in 11, pharyngitis in 7, pneumonia and acute otitis media in 5, acute otitis media in 3, orbital cellulitis in 1, and arthritis in 1. All of the patients had fever and temperatures and 35 (87.5%) of them were more than 39 degrees C. Ten patients had a febrile convulsion. Twenty-nine had a high total white blood cell counts (> 15,000/microg/ml) and 31 had positive CRP values (> 0.6 mg/dl) on admission. Meningitis and poor prognosis did not occur after occult bacteremia in our patients. We studied the susceptibility to penicillin G in 22 strains of S. pneumoniae isolated from the children. One and 18 strains were penicillin-resistant (MIC > or = 2.0 microg/ml) and intermediate (MIC 0.1-1.0 microg/ml).
 ...
PMID:[Study of Streptococcus pneumoniae bacteremia in children]. 1571 76

The effect of infectious bronchitis virus (IBV) infection (10(4.5) median embryo infective dose per chick) on the induction of Mycoplasma synoviae arthritis was investigated. Mycoplasma-free brown layer pullets, approximately 5 weeks old, were exposed to an aerosol dose of > or =10(2-3) colony-forming units (CFU) of M. synoviae alone or 3 days after inoculation of a field strain of IBV (D1466) by the ocular-nasal route. Chicks injected intravenously with 10(9) CFU M. synoviae served as positive controls. Thirty-one per cent of chicks receiving M. synoviae aerosol alone developed arthritis compared with 50% of those co-infected with IBV. Ninety-five per cent of positive control birds developed arthritis. In a repeat experiment an additional group was exposed to M. synoviae aerosol 3 days after infection with IBV M41 strain. These birds also received two aerosol doses of M. synoviae 14 days apart (> or =10(0-1) CFU/bird initially and > or =10(1-3) after 14 days). Chicks injected intravenously with 10(6) CFU M. synoviae acted as positive controls. Fifty per cent of the positive controls were re-inoculated intravenously (10(8) CFU) after 14 days. Twenty-one per cent of chicks infected with M. synoviae aerosol developed arthritis compared with 33% of those co-infected with IBV D1466, and 55% of those co-infected with IBV M41. After the single intravenous, low-dose M. synoviae inoculation 11% of birds developed joint lesions, whereas 70% of those receiving the second inoculation developed lesions. These results suggest that IBV may enhance M. synoviae arthritis after aerosol exposure and that the incidence of joint pathology depends on the strain of IBV.
 ...
PMID:Aerosol-induced Mycoplasma synoviae arthritis: the synergistic effect of infectious bronchitis virus infection. 1576 28

The medicinal plants are widely used by the traditional medical practitioners for curing various diseases in their day to day practice. In traditional systems of medicine, different parts (leaves, stem, flower, root, seeds and even whole plant) of Ocimum sanctum Linn (known as Tulsi in Hindi), a small herb seen throughout India, have been recommended for the treatment of bronchitis, bronchial asthma, malaria, diarrhea, dysentery, skin diseases, arthritis, painful eye diseases, chronic fever, insect bite etc. The Ocimum sanctum L. has also been suggested to possess antifertility, anticancer, antidiabetic, antifungal, antimicrobial, hepatoprotective, cardioprotective, antiemetic, antispasmodic, analgesic, adaptogenic and diaphoretic actions. Eugenol (1-hydroxy-2-methoxy-4-allylbenzene), the active constituent present in Ocimum sanctum L., has been found to be largely responsible for the therapeutic potentials of Tulsi. Although because of its great therapeutic potentials and wide occurrence in India the practitioners of traditional systems of medicine have been using Ocimum sanctum L. for curing various ailments, a rational approach to this traditional medical practice with modern system of medicine is, however, not much available. In order to establish the therapeutic uses of Ocimum sanctum L. in modern medicine, in last few decades several Indian scientists and researchers have studied the pharmacological effects of steam distilled, petroleum ether and benzene extracts of various parts of Tulsi plant and eugenol on immune system, reproductive system, central nervous system, cardiovascular system, gastric system, urinary system and blood biochemistry and have described the therapeutic significance of Tulsi in management of various ailments. These pharmacological studies have established a scientific basis for therapeutic uses of this plant.
 ...
PMID:Therapeutic uses of Ocimum sanctum Linn (Tulsi) with a note on eugenol and its pharmacological actions: a short review. 1617 Sep 79


<< Previous 1 2 3 4 5 Next >>